Subgroup Analyses of Phase 2 Study: Evaluating the Efficacy of Fully Human BCMA-Targeting CAR T Cells (Zevorcabtagene Autoleucel) in Patients with Relapsed/Refractory Multiple Myeloma
Year: 2024
Type: conference-abstract
Source: Blood
Authors: Wenming Chen, Chengcheng Fu, Baijun Fang, Aibin Liang, Zhongjun Xia, Yanjuan He, Jin Lu, Hui Liu, Ming Hou, Zhen Cai, Wei Yang, Siguo Hao, Songfu Jiang, Hongmei Jing, Jing Liu, Xin Du, Rong Fu, Heng Mei, Zunmin Zhu, Yanli Yang, Hong Liu, Xingxing Meng, Nishanthan Rajakumaraswamy, Wei Zheng, Huamao Wang, Zonghai Li
Institutions: Capital Medical University, Beijing Chao-Yang Hospital, Capital Medical University, First Affiliated Hospital of Soochow University, Zhengzhou University, Henan Cancer Hospital, Tongji University, Sun Yat-sen University, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Central South University, Xiangya Hospital Central South University, Peking University People's Hospital, Nantong University, Affiliated Hospital of Nantong University, Beijing Hospital, Qilu Hospital of Shandong University, First Affiliated Hospital Zhejiang University, Zhejiang University, China Medical University, Shanghai Jiao Tong University, XinHua Hospital, First Affiliated Hospital of Wenzhou Medical University, Peking University Third Hospital, Third Xiangya Hospital, Shenzhen University, Shenzhen Second People's Hospital, Tianjin Medical University General Hospital, Tianjin Medical University, Wuhan Union Hospital, Huazhong University of Science and Technology, Henan Provincial People's Hospital, First Affiliated Hospital of Bengbu Medical College
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4405040008